Literature DB >> 8372162

The P50 component of the auditory evoked potential and subtypes of schizophrenia.

N Boutros1, G Zouridakis, T Rustin, C Peabody, D Warner.   

Abstract

Decreased amplitude of the P50 component of the averaged evoked potential has been reported in schizophrenic patients. In an attempt to determine the relationship of this decrease to subtype diagnosis, we compared P50 amplitudes in 24 neuroleptic-free schizophrenic patients with paranoid (n = 13) versus nonparanoid (n = 11) subtype diagnoses. Eleven normal subjects and 11 cocaine users served as control groups. The schizophrenic patients were studied again after they had been treated with neuroleptics for 2 weeks. The control groups were studied again at least 2 weeks later. At baseline, the nonparanoid patients had significantly lower P50 amplitudes than did the normal subjects. The paranoid patients did not differ from the normal control subjects. The cocaine users had significantly decreased P50 amplitudes as compared with the normal control subjects. Neuroleptic treatment had no effect on P50 amplitudes in the paranoid patients but normalized amplitudes in the nonparanoid patients. The data suggest that P50 measurements may be useful in identifying subtypes of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8372162     DOI: 10.1016/0165-1781(93)90082-r

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  13 in total

Review 1.  Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.

Authors:  David Potter; Ann Summerfelt; James Gold; Robert W Buchanan
Journal:  Schizophr Bull       Date:  2006-02-09       Impact factor: 9.306

Review 2.  The status of spectral EEG abnormality as a diagnostic test for schizophrenia.

Authors:  Nash N Boutros; Cynthia Arfken; Silvana Galderisi; Joshua Warrick; Garrett Pratt; William Iacono
Journal:  Schizophr Res       Date:  2007-12-21       Impact factor: 4.939

3.  P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.

Authors:  Bob Oranje; Bodil Aggernaes; Hans Rasmussen; Bjorn H Ebdrup; Birte Y Glenthøj
Journal:  Schizophr Bull       Date:  2012-01-12       Impact factor: 9.306

4.  Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma.

Authors:  J M Phillips; R S Ehrlichman; S J Siegel
Journal:  Neuroscience       Date:  2006-12-19       Impact factor: 3.590

5.  Critical evaluation of auditory event-related potential deficits in schizophrenia: evidence from large-scale single-subject pattern classification.

Authors:  Andres H Neuhaus; Florin C Popescu; Johannes Rentzsch; Jürgen Gallinat
Journal:  Schizophr Bull       Date:  2013-10-22       Impact factor: 9.306

Review 6.  Pre-attentive processing and schizophrenia: animal studies.

Authors:  Bart A Ellenbroek
Journal:  Psychopharmacology (Berl)       Date:  2003-12-04       Impact factor: 4.530

7.  Diagnostic specificity of neurophysiological endophenotypes in schizophrenia and bipolar disorder.

Authors:  Jason K Johannesen; Brian F O'Donnell; Anantha Shekhar; John H McGrew; William P Hetrick
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

8.  Evidence for impaired sound intensity processing during prepulse inhibition of the startle response in a rodent developmental disruption model of schizophrenia.

Authors:  Samuel G Ewing; Anthony A Grace
Journal:  J Psychiatr Res       Date:  2013-08-08       Impact factor: 4.791

9.  Deep brain stimulation of the ventral hippocampus restores deficits in processing of auditory evoked potentials in a rodent developmental disruption model of schizophrenia.

Authors:  Samuel G Ewing; Anthony A Grace
Journal:  Schizophr Res       Date:  2012-12-24       Impact factor: 4.939

10.  Functional abnormalities in the cortical processing of sound complexity and musical consonance in schizophrenia: evidence from an evoked potential study.

Authors:  Kuan-Yi Wu; Ching-Wen Chao; Ching-I Hung; Wei-Hong Chen; Yung-Ting Chen; Sheng-Fu Liang
Journal:  BMC Psychiatry       Date:  2013-05-30       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.